Previous 10 | Next 10 |
AL002 is the first product candidate targeting TREM2 in Phase 2 clinical development Study will enroll early Alzheimer’s disease patients at up to 90 sites globally Alzheimer’s disease is a devastating neurological disease affecting nearly six million peopl...
Alector's (ALEC) chief business officer Sabah Oney, Ph.D., will be leaving the company to pursue other opportunities; Shehnaaz Suliman, M.D., MBA, M.Phil., president and COO will serve as interim CBO.Transition will be effective as of Feb. 1 and Dr. Oney will remain as an ...
Sabah Oney steps down from a role held since January 2018; joined Alector in October 2016 The departure will be effective February 1, 2021; will assist in transition until May 3, 2021 SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq:...
Alector's (ALEC) mid-and-late stage clinical trials for frontotemporal dementia and Alzheimer’s disease are advancing with updated data from ongoing AL001 Phase 2 study in frontotemporal dementia expected in 2021.The updated findings will include safety, fluid biomarkers, imaging bioma...
Clinical trials advancing for Phase 3 in frontotemporal dementia and Phase 2 in Alzheimer’s disease Updated data from ongoing AL001 Phase 2 study in frontotemporal dementia expected in 2021 The Company continues to maintain a strong balance sheet with more...
Alector is a leader in neuroimmunology drug development. This has enabled the company to build a pipeline of medicines pursuing large and important markets from dementia and Alzheimer’s. With margin of safety in the form of a strong balance sheet (over $500M in cash), Alect...
Alector, Inc (Nasdaq: ALEC) is a clinical-stage biopharmaceutical company focused on immuno-neurology, immune dysfunction studies related to degenerative brain disorders. Alector has 4-clinical phase therapeutics entirely targeting primarily neurological diseases including Alzhei...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer of Alector, will participate in a fireside chat at the Stifel ...
G lobal Phase 3 INFRONT-3 trial evaluating AL001 for treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) currently enrolling participants On track to initiate Phase 2 study for AL002 in Alzheimer’s dise...
Independent arbitrator finds in favor of Alector in confidential arbitration proceedings Dr. Abeliovich remains bound by contractual obligations related to the confidentiality of the company’s intellectual property rights SOUTH SA...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...